C3L-03463
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 62.84188912
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- ANGIOGENESIS+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- BILE_ACID_METABOLISM+0.240
- COAGULATION+0.240
- HEME_METABOLISM+0.220
- KRAS_SIGNALING_UP+0.210
- ESTROGEN_RESPONSE_EARLY+0.180
- TGF_BETA_SIGNALING+0.180
- HEDGEHOG_SIGNALING+0.160
Top 10 suppressed
- E2F_TARGETS-0.610
- MYC_TARGETS_V2-0.580
- G2M_CHECKPOINT-0.570
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.490
- MYC_TARGETS_V1-0.450
- DNA_REPAIR-0.370
- OXIDATIVE_PHOSPHORYLATION-0.370
- MITOTIC_SPINDLE-0.320
- MTORC1_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02165 | — | cohortA2 | 0.882 |
| 2 | SRR8518225 | — | B | 0.865 |
| 3 | C3L-01890 | — | cohortA2 | 0.846 |
| 4 | SRR8518184 | — | F | 0.836 |
| 5 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.834 |
| 6 | SRR8518453 | — | F | 0.832 |
| 7 | TCGA-99-8032-01A-11R-2241-07 | — | cohortA3 | 0.831 |
| 8 | TCGA-55-6983-01A-11R-1949-07 | — | cohortA3 | 0.830 |
| 9 | C3N-02193 | — | cohortA1 | 0.827 |
| 10 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |